| Topical term | klinické zkoušky, fáze IV jako téma
|
|---|
| See link | Clinical Trials, Phase 4 as Topic (UF)
|
|---|
| Drug Evaluation, FDA Phase 4 as Topic (UF)
|
|---|
| Drug Evaluation, FDA Phase IV as Topic (UF)
|
|---|
| evaluační studie, FDA fáze IV (UF)
|
|---|
| Evaluation Studies, FDA Phase 4 as Topic (UF)
|
|---|
| Evaluation Studies, FDA Phase IV as Topic (UF)
|
|---|
| klinické hodnocení fáze IV (UF)
|
|---|
| klinické hodnocení léčiv, fáze IV (UF)
|
|---|
| klinické hodnocení léčiv, FDA fáze IV (UF)
|
|---|
| klinické zkoušky - fáze IV - jako téma (UF)
|
|---|
| See also | klinické zkoušky jako téma
|
|---|
| postmarketingový dozor
|
|---|
| nežádoucí účinky léčiv (RT)
|
|---|
| Linking entry | Clinical Trials, Phase IV as Topic
|
|---|
| Conspect | E05. - 318. - 372. - 250. - 250. - 230
|
|---|
| E05. - 337. - 800. - 200
|
|---|
| N05. - 715. - 360. - 330. - 250. - 250. - 230
|
|---|
| N06. - 850. - 520. - 450. - 250. - 250. - 230
|
|---|
| Note | Works about planned post-marketing studies of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques that have been approved for general sale. These studies are often conducted to obtain additional data about the safety and efficacy of a product. This concept includes phase IV studies conducted in both the U.S. and in other countries.
|
|---|
| Database | MESH
|
|---|
| References | (4) - MESH
|
|---|
